Avantor, Inc.
AVTR
Positions held
Your positionsAVTR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Avantor operates in the growing healthcare sector, which is expected to expand as demand for medical instruments and supplies increases.
- Revenue increased by 7% compared to the prior quarter, reaching $1.7 billion.
- Gross margin remained stable at 31.7% compared to the previous quarter.
- The company has faced challenges with earnings growth, showing a decline of 37.4% year-over-year.
- Net income for 2025 was reported at -$530.2 million, indicating significant financial struggles.
- The operating margin has decreased from 12.3% in 2023 to 8.3% in 2025, reflecting ongoing operational inefficiencies.
Fundamentals
| Market cap | $10.41B | Enterprise value | $13.80B | Trailing P/E | — | Forward P/E | 17.54 |
| PEG | — | Price / book | 1.85 | Beta | 0.94 | Dividend yield | 0.00% |
| Revenue growth | 0.5% | Earnings growth | -37.4% | Gross margin | 31.8% | Operating margin | 7.2% |
| Profit margin | -8.8% | ROE | -9.7% | ROA | 2.7% | Debt / equity | 0.66 |
| Current ratio | 1.78 | Free cash flow | $450.34M | Analyst recommendation | hold | Mean target | $14.85 |
| 52w high | $16.38 | 52w low | $7.27 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.6B | $1.7B | $1.6B | $1.7B | — |
| Op margin | 7.2% | 6.3% | 7.9% | 8.4% | 7.7% | — |
| Net income | $38.1M | $43.3M | $52.4M | -$712M | $64.7M | — |
| Gross margin | 31.7% | 31.7% | 31.5% | 32.4% | 32.9% | — |
| Gross profit | $537M | $501M | $524M | $527M | $554M | — |
| Operating income | $122M | $99.5M | $132M | $136M | $129M | — |
- Revenue +7% vs prior quarter ($1.7B vs $1.6B).
- Gross margin 31.7% (was 31.7% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.6B | $6.8B | $7.0B | $7.5B | — |
| Op margin | 8.3% | 9.4% | 12.3% | 15.0% | — |
| Net income | -$530M | $712M | $321M | $687M | — |
| Gross margin | 32.7% | 33.6% | 33.9% | 34.6% | — |
| Gross profit | $2.1B | $2.3B | $2.4B | $2.6B | — |
| Operating income | $544M | $638M | $857M | $1.1B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
2026-10-08 · Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock?
2026-10-07 · AeraHUB 26 NYC Brings the Decision-Centric Enterprise to Life
2026-10-06 · VTRS vs. AVTR: Which Stock Is the Better Value Option?
2026-10-01 · Q2 Earnings Review: Research Tools & Consumables Stocks Led by Avantor (NYSE:AVTR)
2026-10-01 · Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026
2026-09-29 · 3 Unprofitable Stocks with Open Questions
2026-09-22 · How Avantor’s New CFO Appointment At Avantor (AVTR) Has Changed Its Investment Story
2026-09-21 · Are Medical Stocks Lagging Avantor (AVTR) This Year?
2026-09-21 · Avantor Names Todd Garner as CFO
2026-09-21 · Avantor appoints new Chief Financial Officer
2026-09-18 · Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
Price (daily)
Full chart · RSI · MACD · patterns